The Drugs Controller General of India (DCGI) has approved the market authorization of India’s first quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Serum Institute of India (SII) will produce this vaccine. CEO of The Serum Institute of India Adar Poonawalla tweeted the information. For the first time, an inexpensive and widely available HPV vaccination made in India will be available to treat cervical cancer in female patients. Later this year, SII hopes to launch it, and we are grateful to the DCGI, MoHFW INDIA, for their approval.
Following an assessment of the clinical trial results for the vaccine, the National Technical Advisory Group on Immunization (NTAGI) recently gave its approval to the qHPV. The Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer, which was produced domestically by Serum Institute of India (SII), was recommended for standard market authorization on June 15. After the vaccine’s phase 3 data were deemed to be satisfactory, suggestions were made.
Important Takeaways For All Competitive Exams:
In today's world, taxes take up a big part of our income in most countries.…
Introduction Kamchatka is a vast, wild, and geologically remarkable peninsula in the Far East of…
In 2025, India's biggest companies continue to show their strength both at home and around…
Earthquakes are among the most powerful natural disasters on Earth, capable of shaking the ground,…
The National Education Policy (NEP) 2020, India’s third education policy since Independence, was introduced as…
What is a Tsunami? – Definition & Overview A tsunami is a series of huge…
![](data:image/svg+xml;charset=utf-8,<svg height="218px" width="300px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
